Healthpeak Properties, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Healthpeak Properties, Inc. stock analysis DOC overview
Bullish +75

Key Reasons to Add Healthpeak Properties Stock to Your Portfolio Now - Zacks Investment Research

📈 Healthpeak Properties (DOC) is strategically positioned to capitalize on robust demand for lab assets and anticipated increases in senior citizens' healthcare spending.

💰 The company recently closed a new $400 million unsecured delayed-draw term loan facility, which enhances its liquidity and financial flexibility.

🏢 In the same month, Healthpeak monetized senior housing assets through Janus Living Inc.'s IPO, generating net proceeds of $878 million for acquisitions and corporate purposes.

🔬 Growing life expectancy and biopharma R&D growth are driving demand for lab real estate, with AI usage expected to further accelerate drug research success rates.

📝 Healthpeak secured significant lab lease agreements totaling 333,000 square feet in the fourth quarter of 2025, reflecting its ability to meet growing tenant demand.

👴 The company's Continuing Care Retirement Community (CCRC) portfolio is well-positioned for rising senior healthcare expenditures, with occupancy at 87.4% in the fourth quarter of 2025.

🔄 Healthpeak is actively repositioning its portfolio to focus on core lab, outpatient medical, and CCRC assets while recycling capital from non-core dispositions.

🏗️ In January 2026, the company acquired a leasehold interest in a Salt Lake City lab campus for approximately $68.2 million, expanding its high-barrier-to-entry market presence.

💸 Healthpeak closed outpatient medical dispositions totaling about $325 million in the fourth quarter of 2025, covering 834,000 square feet of stabilized assets.

🛡️ As of December 31, 2025, Healthpeak reported total liquidity of approximately $2.39 billion with a net debt-to-adjusted EBITDA ratio of 5.2X.

🏦 The company holds strong credit ratings of Baa1 (Stable) from Moody's and BBB+ (Stable) from S&P Global, ensuring favorable access to the debt market.

📉 Despite a Zacks Rank #2 (Buy) rating, analyst sentiment is bearish with 2026 AFFO per share estimates lowered by 5.4% over the past two months to $1.76.

📉 Stock shares of DOC have declined 2.6% over the past month, outperforming the industry growth rate of 1.3%.

🚀 Analysts suggest considering other top-ranked REIT stocks like Crown Castle Inc. (CCI) and Prologis (PLD), both carrying a Zacks Rank #2.

💡 FFO metrics are used to gauge performance in this sector, with CCI's 2026 FFO pegged at $4.43 and PLD's full-year FFO estimated at $6.14.

📊 Healthpeak's strong balance sheet and strategic acquisitions position it to leverage growth opportunities within the specialized healthcare real estate niche.

Bullish Signals
  • Healthpeak Properties is well-positioned to benefit from robust demand for lab assets and an expected rise in senior citizens' healthcare spending.
  • The company closed on a new $400 million unsecured delayed-draw term loan facility last month, significantly enhancing its liquidity and financial flexibility.
  • Healthpeak monetized senior housing assets through Janus Living, Inc.'s IPO, securing net receipts of $7.8 billion ($878 million) to fund pending acquisitions and general corporate purposes.
  • In the fourth quarter of 2025, Healthpeak executed new lab lease agreements totaling 261,000 square feet, demonstrating strong growth in its high-demand segment.
  • The company's CCRC portfolio showed an occupancy rate of 87.4% in the fourth quarter of 2025, indicating healthy demand for senior housing assets.
  • Healthpeak has a net debt-to-adjusted EBITDA ratio of only 5.2X as of Dec. 31, 2025, reflecting a conservative leverage position that facilitates bank financing.
  • The company holds strong long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global with Stable outlooks, ensuring easy access to the debt market at favorable costs.
  • Zacks maintains a Zacks Rank #2 (Buy) designation for DOC, signaling positive analyst sentiment despite recent short-term share declines.
Risk Factors
  • Analysts are bearish on Healthpeak Properties (DOC), with the Zacks Consensus Estimate for its 2026 AFFO per share lowered 5.4% over the past two months to $1.76.
  • Over the past month, shares of DOC have declined 2.6%, significantly outpacing the industry's growth of 1.3%.
Full Analysis
Healthpeak Properties, Inc. (DOC) is positioned to benefit from strong demand for laboratory assets and rising healthcare spending among the senior population. To bolster its financial flexibility, the company recently closed a $400 million unsecured delayed-draw term loan facility and successfully monetized senior housing assets through the IPO of Janus Living, Inc., which generated $878 million in net proceeds for acquisitions and corporate purposes. These strategic moves support Healthpeak's focus on scaling lab operations, where increased life expectancy and biopharma growth are driving market fundamentals. Additionally, the use of artificial intelligence in drug research is expected to lower development timelines, further increasing demand for laboratory space, with Healthpeak executing new and renewal lab lease agreements totaling 261,000 and 72,000 square feet respectively in the fourth quarter of 2025. The company’s portfolio is also strategically repositioned toward outpatient medical assets and continuing care retirement communities (CCRCs), which are poised to capitalize on the growing senior demographic. In the fourth quarter of 2025, Healthpeak's life plan portfolio maintained an occupancy rate of 87.4%. To fund this transition, the company recycled capital by disposing of non-core assets such as SHOP and triple-net leased properties; notably, it exercised a purchase option on January 26, 2026, to acquire a four-building lab campus in Salt Lake City, UT, for approximately $68.2 million, while closing outpatient medical dispositions worth about $325 million with roughly 834,000 square feet during Q4 2025. Healthpeak maintains a robust balance sheet with total liquidity of around $2.39 billion and a net debt-to-adjusted EBITDA ratio of 5.2X as of December 31, 2025. It holds long-term credit ratings of Baa1 from Moody’s and BBB+ from S&P Global, both stable, ensuring favorable access to the debt market. However, despite holding a Zacks Rank #2 (Buy), analysts have lowered their consensus estimate for 2026 AFFO per share by 5.4% over the past two months to $1.76, and shares declined 2.6% in the last month while the industry grew 1.3%. The article contrasts this with other sector peers like Crown Castle Inc. (CCI) and Prologis (PLD), which also carry a Zacks Rank #2 but show positive earnings growth forecasts for 2026.